Sihuan Pharmaceutical Holdings Group Ltd., the largest cardio-cerebral vascular drug maker in China, announces major participation in the upcoming American Diabetes Association’s 79th Scientific Sessions. Sihuan’s abstracts will be published in the web journal Diabetes.
Among other things, Professor Ji Linong from Peking University People’s Hospital will discuss Janagliflozin associated clinical trial. Specifically they are a first to domestically employ SGLT-2 Inhibitors Quantitative Pharmacologic Models to successful assist the selection of clinical dosages. Other studies:
(1) Pharmacokinetics, Pharmacodynamics, and Tolerability of Single- and Multiple-Dose of Janagliflozin, a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Chinese Subjects. In healthy Chinese subjects, Janagliflozin was generally well tolerated and had favorable pharmacokinetics and pharmacodynamics profiles supporting a once-daily dosing regimen. The present studies suggest Janagliflozin 25 mg and 50 mg could be the clinically recommended doses, which need to be further investigated in T2DM patients.
(2) Pharmacokinetics, Pharmacodynamics, and Tolerability of Single- and Multiple-Dose of Janagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus. Janagliflozin exhibited favorable pharmacokinetics profiles in Chinese patients with T2DM and was well tolerated. Janagliflozin treatments resulted in increase in urinary glucose excretion and improvement in glycemic control. Janagliflozin 25 mg and 50 mg are recommended for further clinical studies.
(3) Accelerating Clinical Development of Janagliflozin, a Novel Anti-Diabetic Drug, using Model-informed Drug Development Strategy. The model-informed drug development (MiDD) strategy exhibited a good capability to accelerate early phase clinical development of Janagliflozin after confirmation from short-term clinical trials.
Dr. Che Fengsheng, Chairman and CEO of Sihuan Pharmaceutical, said, “The Group expects the potential market for SGLT-2 inhibitors in both China and abroad is massive and increasing. The Group has been granted patents for Janagliflozin in China, United States, Europe, Japan and Korea and phase 3 studies of Janagliflozin are ongoing. SGLT-2 inhibitors can be taken as monotherapy or in combination with other anti-diabetic agents. The market for SGLT-2 inhibitors in both China and abroad is massive.”
Dr. Che continued, “In addition, the Group’s other innovative drugs, including CDK4/6 inhibitor ‘Birociclib’ and Proton Pump Inhibitor ‘Anaprazole Sodium’, are progressing well in their respective clinical trials. The progress of these clinical trials demonstrates that the Group has made significant break-through in self-driven research and development of innovative drugs and established a solid foundation for a comprehensive innovative drug platform.
About Sihuan Pharmaceutical Holdings Group Ltd
Formed in 2001, Sihuan Pharmaceutical Holdings Group Ltd. has achieved sound development in the past years and has grown into the leading pharmaceutical company in China’s prescription drug market. The Group has been the largest cardio-cerebral vascular drug franchise in China’s prescription drug market since 2007. The success of the Group can be attributed to its unique and proven sales & marketing model, extensive nationwide distribution network, diversified portfolio of market-leading drugs, and strong research & development capabilities.Source: PR Newswire